Photodynamic therapy (PDT) is a well-established treatment modality for cancer and other malignant diseases; however, quantities such as light fluence, and PDT dose do not fully account for all of the dynamic interactions between the key components involved. In particular, fluence rate (ϕ) effects are not accounted for, which has a large effect on the oxygen consumption rate. In this preclinical study, reacted reactive oxygen species ([ROS]rx) was investigated as a dosimetric quantity for PDT outcome. We studied the ability of [ROS] [ROS]rx is determined to be 0.23 mM and is about 4.3 times smaller than the corresponding value for conventional BPDmediated PDT using DLI of 3 hrs.
INTRODUCTION
Photodynamic therapy (PDT) is a used for treatment of cancer and other localized diseases. PDT leads to fewer side effects than radiation and chemotherapy, because it does not involve ionizing radiation and can be well-localized 1, 2 . Widespread use of PDT has been stilted due to the difficulty in accurately quantifying the dose. PDT is not only "dynamic" but also multifaceted 3, 4 . It incorporates light, photosensitizer, and oxygen to create activated singlet oxygen ( 1 O2) to kill cells. To address the need for better dosimetry in PDT, we have developed a singlet oxygen explicit dosimetry model to predict PDT outcome [5] [6] [7] [8] . The four major photochemical parameters in a macroscopic singlet oxygen model have been investigated and determined for the photosensitizer benzoporphyrin derivative monoacid A (BPD).
In this study, reactive oxygen species explicit dosimetry (ROSED) was performed using measured values of light fluence rate, photosensitizer concentration and [ROS] to evaluate the treatment outcomes of BPD-mediated vascular PDT in mice bearing radiation-induced fibrosarcoma (RIF) tumors. Vascular-targeted PDT can be achieved using a short (15 minute) drug light interval 9 . By inducing vascular shutdown, nutrient supply and removal of metabolic waste is halted which results in RIF tumor cell death. This is beneficial because tumor vasculature is easy to access for targeting, and vascular damage is efficient in cancer cell killing and has a low likelihood of leading to drug resistance.
MATERIALS AND METHODS

Tumor Model
RIF cells were cultured and 30 μl were injected at 1 × 10 7 cells/ml intradermally over the right shoulders of 6 to 8 weeks old female C3H mice (NCI-Frederick, Frederick, Maryland), as described previously [10] [11] [12] . Animals were under the care of the University of Pennsylvania Laboratory Animal Resources. All studies were approved by the University of Pennsylvania
Institutional Animal Care and Use Committee. Tumors were treated at a size of ∼3 to 5 mm in diameter. Fur within the region of tumor inoculation was clipped prior to injection of cells, and the treatment area was depilated with Nair (Church & Dwight Co., Inc., Ewing, New Jersey) at least 24 h before measurements. Mice were provided a chlorophyll-free (alfalfafree) rodent diet (Harlan Laboratories Inc., Indianapolis, Indiana) starting at least 10 days prior to treatment to eliminate the fluorescence signal from chlorophyll-breakdown products, which have a similar emission range to the BPD fluorescence spectra used to determine the concentration of BPD in the tumor. During the delivery of PDT, mice were kept under anesthesia on a heat pad at 38°C.
PDT Treatment Conditions
PDT was delivered using an optical fiber with a microlens attachment coupled to a diode laser. A 690 nm laser (B&W Tek Inc., Newark, Delaware) was used for PDT after a 15 min drug-light interval. The in-air fluence rate (ϕair) is defined as the calculated irradiance determined by the laser power divided by the treatment area (1 cm diameter spot size). The inair fluence was calculated by multiplying the in-air fluence rate by the treatment time. RIF tumor-bearing mice with no photosensitizer and no light excitation were used as controls (n = 5). Treatment conditions are summarized in Table 1 ) at a dosage of 1 mg∕kg was injected through the mouse tail vein as described previously.
12,13
At a 15 min drug-light interval, superficial irradiation of the tumor was performed with a 690-nm laser (B&W Tek Inc., Newark, Delaware). A microlens fiber was coupled to the laser to irradiate the tumor uniformly. Animals were assigned to four light dose groups, and each group was comprised of 2 to 3 subgroups with different ϕ. There were a total of 6 treatment groups: 22. 
Oxygen Measurements
The in vivo tissue oxygen partial pressure pO2 was measured during PDT treatment using a phosphorescence-based ROS 
BPD Concentration
Following the drug-light interval of 15 min, measurements of light fluence rate, photosensitizer concentration and [ROS] were performed. BPD fluorescence spectra was obtained using a custom-made multi-fiber contact probe before and after PDT. 17 The probe is connected to a 405 nm laser (Power Technology Inc., Little Rock, AR, USA) for the fluorescence excitation of BPD and a multichannel CCD spectrograph (InSpectrum, Princeton Instruments, Trenton, NJ, USA) for the collection of the spectra. The in vivo photosensitizer concentration was obtained by comparing the in vivo BPD spectra with those of phantoms with known photosensitizer concentrations. The attenuation of the fluorescence signal due to light absorption and scattering by tissues was corrected by applying an empirical correction factor described elsewhere. 16 The accuracy of in vivo measurements was validated by ex vivo measurements in separate mice.
19
Tumor Regrowth Rate Analysis
Tumor volumes were measured daily after PDT. Width (a) and length (b) were measured with slide calibers, and tumor volumes (V) was calculated using V = π × a 2 × b∕6. 20 Tumor volumes were tracked for 14 days, and the tumor regrowth factor (k) was calculated by the best exponential fit [with a form f(d) = Ae kd ] to the measured volumes over the days (d).
CI was calculated for each treatment group as
where k is the tumor regrowth factor for each group and kctr is the regrowth factor for the control group, which consisted of tumors exposed to neither BPD nor light illumination.
Reactive Oxygen Species Explicit Dosimetry
Type II PDT process can be described by a set of kinetic equations which can be simplified to describe the creation of 
where ϕ is the light fluence rate, S is the source term, μa and μs' are the absorption and reduced scattering coefficients, respectively. The five parameters involved in the kinetic equations are photosensitizer-specific and details of each can be found elsewhere. 21 ξ is the photochemical oxygen consumption rate per light fluence rate and photosensitizer concentration under ample ROS supply. β represents the ratio of the monomolecular decay rate of the triplet state photosensitizer to the bimolecular rate of the triplet photosensitizer quenching by ROS. g is the maximum macroscopic oxygen perfusion rate. 
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